

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

June 5, 2023

To Shareholders,

Company Name Renascience Inc
Representative: Koji Naito, President & CEO
(Code: 4889 TSE Growth)
Inquiries: Department of Administration

**Notice of Conclusion of Collaboration Agreement with
Kyoto University and Daiichi Sankyo Company, Limited**

The Company is pleased to announce that the Company has executed a collaboration agreement (hereinafter “Agreement”) with Kyoto University (Location: Kyoto, Japan; President: Nagahiro Minato) and Daiichi Sankyo Company, Limited (Location: Chuo-ku, Tokyo; President & COO: Hiroyuki Okuzawa; hereinafter "Daiichi Sankyo").

Although this matter does not fall under the category of timely disclosure as stipulated by the rules of the Tokyo Stock Exchange, the Company voluntarily discloses this information because the Company believes it is useful for the Shareholders.

1. Background of Agreement

Non-clinical studies have shown that the PAI-1 inhibitor RS5614 inhibits inflammation and fibrosis in the lungs. The Company therefore conducts research and development of the PAI-1 inhibitor RS5614 in the area of lung injury due to various causes, including viral infections such as SARS-CoV-2 (COVID-19), anticancer agents, autoimmune diseases, and idiopathic diseases.

The Company has entered into a collaboration agreement with Kyoto University dated December 23, 2022, with a view to conducting a clinical trial of RS5614 for the treatment of acute exacerbations of idiopathic pulmonary fibrosis. The Company also granted Daiichi Sankyo a preferential negotiating right with option rights to develop and commercialize RS5614 as a drug candidate for the treatment of pulmonary disorders, on December 25, 2020, and extended the agreement until March 31, 2025, to further confirm the efficacy of this drug candidate in the area of lung disorders (November 28, 2022). To expand the research and development in lung disorders, Kyoto University, Daiichi Sankyo and the Company now execute the Agreement.

2. Outline of collaboration partners

(1) Kyoto University

Name	Kyoto University
Location	Yoshida Honmachi, Sakyo-ku, Kyoto-shi, Kyoto
Name and title of representative	President Nagahiro Minato
Capital	157.7 billion yen

Date of establishment	Kyoto University established as a national university corporation in April 2004 (Kyoto University founded in June 1897)
Relationship with Kyoto University	Kyoto University and the Company have been conducting a collaboration on the development of diagnostic support program for respiratory function test (spirometry) utilizing an artificial intelligence (AI). In addition, Kyoto University and the Company have been collaborating on investigator-initiated clinical trials (Phase IIa and IIb) for novel coronavirus lung injury, which has been conducted jointly by a number of universities and medical institutions. In addition, Kyoto University and the Company have entered into a collaboration agreement for RS5614 for lung injury. There are no other capital relationships, personal relationships, or related party relationships.

(2) Daiichi Sankyo Company, Limited

Name	Daiichi Sankyo Company, Limited
Location	Nihonbashi-Honcho, Chuo-ku, Tokyo
Name and title of representative	Hiroyuki Okuzawa, President & COO
Capital	50 billion yen
Date of establishment	September 28, 2005
Relationship with Daiichi Sankyo Company, Limited	Daiichi Sankyo and the Company have entered into a preferential negotiating rights agreement with option rights, and the Company has granted to Daiichi Sankyo a preferential negotiating rights with option rights to license the development and commercialization of RS5614, the Company's lung disease drug candidate.

3. Outlook for the future

This matter will have no impact on the business performance of the Company.

End